Jens Fleckenstein

University Medical Centre Mannheim

Papers

2

Total Citations

33

H-Index

2

About

Jens Fleckenstein is a leading figure in stereotactic body radiotherapy (SBRT), with a focused expertise in motion-compensated treatments for liver metastases and the emerging field of cardiac radioablation. His most impactful work, a pooled multi-platform analysis of liver SBRT with active motion compensation, demonstrated excellent local control for oligometastases, a finding that has garnered 21 citations and helped establish best practices for treating moving tumors. Dr. Fleckenstein also played a pivotal role in the RAdiosurgery for VENtricular TAchycardia (RAVENTA) trial, where he led a multicenter, multiplatform benchmarking study for treatment planning in cardiac radioablation—a non-invasive approach to managing ventricular tachycardia. This work, with 12 citations, provides critical standardization for a highly complex procedure. By bridging technical precision in motion management with clinical outcomes, Fleckenstein’s research directly advances the safety and efficacy of SBRT for both hepatic and cardiac indications, making him a key contributor to the translation of advanced radiotherapy techniques into routine clinical practice.

Research Focus

Key Achievements

2
H-Index
2
Papers
33
Total Citations
17
Avg Citations/Paper
🏆 Most Cited Paper
Liver SBRT with active motion-compensation results in excellent local control for liver oligometastases: An outcome analysis of a pooled multi-platform patient cohort
21 citations · 2021
📈 Most Prolific Year: 2021 (1 Papers)
🤝 Key Collaborators: 33
🏛 Institutions: University Medical Centre Mannheim

Top Papers

  1. 1
  2. 2

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 12 days ago